News

The FDA has granted a priority review designation to a biologics license application for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.

Faculty from NewYork-Presbyterian Hospital/Columbia University Irving Medical Center share their resolutions for the new year and the efforts being made to improve patient outcomes in practice.

William K. Oh, MD, sheds light on how he approaches treatment in patients with metastatic hormone-sensitive prostate cancer.

Peter Voorhees, MD, provides an overview of the many developments made with CAR T-cell therapy in multiple myeloma, as well as the exciting research being done with bispecific antibodies

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Simon Rule, MD, PhD, discusses pooled findings examining ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Katherine D. Crew, MD, discusses the results of HER2CLIMB and DESTINY-Breast01, as well as other impactful data in HER2-positive breast cancer that emerged from the 2019 San Antonio Breast Cancer Symposium.

The FDA has extended the Prescription Drug User Fee Act deadline for a new drug application for avapritinib as a treatment for adult patients with fourth-line gastrointestinal stromal tumor.

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

Rita Nanda, MD, discusses ongoing advances with immunotherapy in triple-negative breast cancer, as well as develops in the HER2-negative breast cancer paradigm.

Lee Schwartzberg, MD, FACP, advocates for the increased use of biosimilars in oncology and discusses the benefits of these agents for patients and providers.

Eileen Connolly, MD, PhD, reflects on novel radiation techniques, as well as ongoing research and challenges with radiation therapy in breast cancer.

Antonio González-Martín, MD, discusses the design and findings of the PRIMA trial in advanced ovarian cancer.

The Association of Community Cancer Centers is pleased to announce that its Multidisciplinary Chronic Lymphocytic Leukemia Care education project is conducting a series of quality improvement workshops to promote the optimal care and management of patients diagnosed with chronic lymphocytic leukemia.

Katherine D. Crew, MD, discusses the updated results of the KATHERINE trial, as well as other data regarding the adjuvant treatment paradigm in early-stage HER2-positive breast cancer.

Thomas J. Polascik, MD, discusses the growing relevance of genetic testing for men with prostate cancer and those at a high risk of developing the disease.

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Roy S. Herbst, MD, PhD, discusses research regarding immunotherapy and accompanying biomarkers in non–small cell lung cancer.

Following significant progress made in the development of novel systemic therapies for patients with cancer, the role of surgery in oncology continues to evolve. To this end, ASCO has selected the refinement of surgical treatment of cancer as its Advance of the Year.

Melissa K. Accordino, MD, MS, discusses the treatment options for patients with hormone receptor-positive, HER2-negative breast cancer.

James M. Reuben, PhD, MBA, discusses his research on using liquid biopsies to identify predictive biomarkers for immunotherapy in patients with metastatic breast cancer.

Dawn L. Hershman, MD, MS, discusses current treatment considerations in premenopausal women with early-stage, hormone receptor-positive breast cancer.

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for the rituximab biosimilar PF-05280586 for the treatment of patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.